Finepoint Capital LP Grows Position in Prothena Co. plc (NASDAQ:PRTA)

Finepoint Capital LP increased its position in Prothena Co. plc (NASDAQ:PRTA) by 51.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 657,071 shares of the biotechnology company’s stock after buying an additional 223,600 shares during the quarter. Prothena accounts for approximately 0.6% of Finepoint Capital LP’s holdings, making the stock its 15th biggest holding. Finepoint Capital LP owned about 1.22% of Prothena worth $9,100,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in PRTA. Headlands Technologies LLC increased its position in shares of Prothena by 196.5% in the fourth quarter. Headlands Technologies LLC now owns 7,330 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 4,858 shares during the period. Teacher Retirement System of Texas bought a new position in Prothena during the 4th quarter valued at approximately $145,000. Purkiss Capital Advisors LLC purchased a new stake in Prothena in the 4th quarter worth approximately $149,000. China Universal Asset Management Co. Ltd. grew its position in shares of Prothena by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,409 shares of the biotechnology company’s stock worth $158,000 after buying an additional 1,065 shares during the last quarter. Finally, Chicago Partners Investment Group LLC bought a new stake in shares of Prothena in the 4th quarter worth approximately $159,000. 97.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently commented on PRTA shares. Oppenheimer raised their price target on Prothena from $58.00 to $62.00 and gave the stock an “outperform” rating in a research note on Friday, February 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Prothena in a research report on Friday, February 21st. HC Wainwright reissued a “buy” rating and issued a $48.00 price target on shares of Prothena in a research note on Friday, February 21st. Royal Bank of Canada cut their price objective on Prothena from $24.00 to $20.00 and set a “sector perform” rating on the stock in a research report on Friday, February 21st. Finally, Bank of America decreased their target price on Prothena from $26.00 to $22.00 and set a “neutral” rating for the company in a research report on Thursday, December 19th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $55.00.

Prothena Trading Down 4.1 %

Shares of NASDAQ:PRTA opened at $10.86 on Friday. Prothena Co. plc has a 12-month low of $10.68 and a 12-month high of $25.42. The stock has a market capitalization of $584.56 million, a price-to-earnings ratio of -4.72 and a beta of -0.02. The stock has a fifty day simple moving average of $14.02 and a two-hundred day simple moving average of $15.23.

Prothena (NASDAQ:PRTA) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.06). The firm had revenue of $2.12 million for the quarter, compared to analysts’ expectations of $7.53 million. Prothena had a negative net margin of 90.50% and a negative return on equity of 22.67%. As a group, equities research analysts predict that Prothena Co. plc will post -4.04 EPS for the current year.

Prothena Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.